SEC Form 10-Q Summary
Filing identity: The request identifies FitLife Brands, Inc., but the supplied filing is for Bond Laboratories, Inc., formerly or otherwise associated with the BNLB ticker. The report covers the quarter and nine months ended September 30, 2011, and was filed November 10, 2011.
Business Context and Reporting Period
Bond Laboratories develops and markets nutritional supplements, primarily through NDS Nutrition Products, Inc. and General Nutrition Centers franchise locations. Management focused working capital and operations on the NDS product line while evaluating a potential sale, spin-off, liquidation, or other disposition of the Fusion Premium Beverages division. The company marketed more than 50 products through over 800 GNC franchise locations, compared with approximately 600 locations in the prior-year period.
The interim financial statements are unaudited and condensed. Management states that results for the nine months ended September 30, 2011 are not necessarily indicative of full-year results.
Financial Performance and Position
| Metric | Three Months Ended September 30 | Nine Months Ended September 30 |
|---|---|---|
| Revenue | $3.220 million, versus $2.042 million | $9.379 million, versus $6.442 million |
| Gross profit | $1.199 million, versus $0.549 million | $3.391 million, versus $1.858 million |
| Gross margin | 37.2%, versus 26.9% | 36.2%, versus 28.8% |
| Operating income/(loss) | $0.298 million, versus $(0.545) million | $0.809 million, versus $(1.520) million |
| Net income/(loss) | $0.291 million, versus $(0.560) million | $0.782 million, versus $(1.581) million |
| Basic EPS | $0.00, versus $(0.01) | $0.01, versus $(0.02) |
Revenue increased approximately 58% for the quarter and 46% for the nine-month period. The shift to higher-margin NDS products and discontinuation of Fusion beverage sales improved gross margins. General and administrative expense declined 42% for the quarter and 36% for the nine months, while selling and marketing expense increased for the quarter but declined for the nine-month period.
Cash and cash equivalents were $299,163 at September 30, 2011, down from $445,662 at December 31, 2010. Accounts receivable increased to $1.152 million from $575,000, and inventory increased to $1.954 million from $1.474 million. Total current assets were $3.432 million and current liabilities were $1.356 million, implying a current ratio of approximately 2.5x.
Total debt and credit facilities were $485,654, consisting of a $48,565 secured promissory note and a $437,089 revolving line of credit. All debt was classified as current. The promissory note matured December 1, 2011 and required monthly payments of $17,350; the $1.0 million line of credit matured May 15, 2012 and was secured by NDS receivables and inventory.
Operating cash flow was approximately negative $1,546 for the nine months, substantially improved from negative $1.080 million in the prior-year period. Working-capital investment included increases of approximately $578,000 in accounts receivable and $481,000 in inventory. Investing activities provided $1,200, while financing activities used $146,153, primarily for debt repayments. Ending stockholders’ equity was $3.659 million, compared with $2.981 million at December 31, 2010.
Material Changes, Outlook, Risks and Unusual Items
- Management attributed the return to profitability to higher NDS sales, expanded GNC distribution, new product launches, improved product mix, and lower Fusion-related operating costs.
- Management expected existing cash resources and anticipated operating cash flow to fund liquidity through at least December 31, 2011, but acknowledged that additional financing could be required if positive operating cash flow is not achieved.
- Management stated that litigation relating to former President Eric Schick could materially reduce future operating cash flow and adversely affect financial condition. The company expects defense costs to be material, although the ultimate outcome and costs cannot be determined.
- An OSHA order found reasonable cause to conclude that the company and its former CEO violated employee-protection provisions, ordered damages, and required reinstatement of Mr. Schick. The company objected and requested a formal administrative hearing.
- A separate CycloBolan product-liability lawsuit sought initial damages of $500,000. The insurer assumed the defense, and management characterized the company’s risk as minimal; the filing states that the potential outcome could not yet be evaluated.
- The company restored $308,000 of deferred-tax valuation allowance based on expected use of net operating losses, but maintained a full valuation allowance against remaining deferred tax assets. Utilization remains subject to Internal Revenue Code Section 382 limitations.
- At September 30, 2011, common shares outstanding totaled 74,171,996. Potential dilution included approximately 15.0 million warrants, 500,000 options, and shares issuable upon conversion of Series C preferred stock.
- The company reported no defaults upon senior securities, no material changes to previously disclosed risk factors, and no subsequent events reasonably likely to affect the financial statements.
Investor Verification Points
- Verify the issuer’s identity, ticker, and relationship between FitLife Brands, Inc. and the Bond Laboratories filing supplied.
- Confirm the repayment or refinancing status of the $48,565 promissory note after its December 1, 2011 maturity and the status of the revolving line of credit.
- Monitor operating cash generation, receivable collections, inventory growth, and the company’s need for additional financing.
- Assess the potential financial impact, timing, and insurance coverage of the Schick/OSHA matter and the CycloBolan litigation.
- Review the sustainability of revenue growth from GNC locations and the margin benefit from concentrating on NDS products.
- Evaluate dilution from preferred-stock conversion, options, warrants, and stock issued for services.